Unknown

Dataset Information

P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma.


ABSTRACT: Glioblastomas are highly aggressive and deadly brain tumours, with a median survival time of 14-18 months post-diagnosis. Current treatment modalities are limited and only modestly increase survival time. Effective therapeutic alternatives are urgently needed. The purinergic P2X7 receptor (P2X7R) is activated within the glioblastoma microenvironment and evidence suggests it contributes to tumour growth. Studies have implicated P2X7R involvement in a range of neoplasms, including glioblastomas, although the roles of P2X7R in the tumour milieu remain unclear. Here, we report a trophic, tumour-promoting role of P2X7R activation in both patient-derived primary glioblastoma cultures and the U251 human glioblastoma cell line, and demonstrate its inhibition reduces tumour growth in vitro. Primary

SUBMITTER: Kan LK 

PROVIDER: S-EPMC10209214 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature